Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies. 

Vir gained exclusive worldwide rights to HER2-targeted, PSMA-targeted, and EGFR-targeted T-cell engager assets.

The company said newly released Phase I/II study data for BBP-631 indicated the program did not merit further capital investment.

The University of Calgary spinout aims to commercialize a liquid biopsy test that measures mRNA biomarkers for the early detection of breast cancer.

GenomOncology's Pathology Workbench will be used as the clinical genomic reporting platform for Precipio's myeloid neoplasm test.

AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.

The company has identified an optimal dose and potential biomarkers of response to PRTH-101 in the Phase I trial.

The firm is also evaluating a test to identify HLA-A2-positive patients eligible for the neoepitope-based cancer vaccine.

The first project in this program to advance gene therapies for very rare conditions will focus on CHAT-mutated congenital myasthenic syndrome.

The antisense oligonucleotide developer plans to use the funds raised to support its independent commercial launches, late-stage clinical programs, and more.